First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid

2015 ◽  
Vol 173 (1) ◽  
pp. 302-304 ◽  
Author(s):  
Y.T. Cho ◽  
C.Y. Chu ◽  
L.F. Wang
Keyword(s):  
Complete Remission ◽  
Combination Therapy ◽  
Bullous Pemphigoid ◽  
Remission Rate ◽  
Complete Remission Rate ◽  
First Line ◽  
High Complete Remission Rate

High Complete Remission Rate in Hairy Cell Leukemia Treated with 2-Chlorodeoxyadenosine

1993 ◽  
Vol 11 (5-6) ◽  
pp. 399-404 ◽  
Author(s):  
F. Lauria ◽  
D. Benfenati ◽  
D. Raspadori ◽  
D. Rondelli ◽  
P. L. Zinzani ◽  
...  
Keyword(s):  
Complete Remission ◽  
Hairy Cell Leukemia ◽  
Remission Rate ◽  
Complete Remission Rate ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
High Complete Remission Rate

Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial

Rheumatology ◽  
2020 ◽  
Author(s):  
Chanyuan Wu ◽  
Qian Wang ◽  
Dong Xu ◽  
Mengtao Li ◽  
Xiaofeng Zeng
Keyword(s):  
Complete Remission ◽  
Connective Tissue ◽  
Connective Tissue Disease ◽  
Remission Rate ◽  
Complete Remission Rate ◽  
Severe Side Effect ◽  
Open Label ◽  
First Line Therapy ◽  
Primary Endpoints ◽  
Significant Difference

Abstract Objectives Connective tissue disease-related thrombocytopenia (CTD-TP) is a problematic disorder in clinical practice. Because the first-line therapy of glucocorticoid and/or immunosuppressants is not effective for refractory cases, alternative treatment approaches are urgently needed. The present study investigated the efficacy and safety of sirolimus in refractory CTD-TP patients. Methods This single-centre, single-arm, phase II study enrolled 20 refractory CTD-TP patients between September 2017 and September 2018 (registered on ClinicalTrials.gov: NCT03688191). Oral sirolimus administration was dose-adjusted to maintain a therapeutic range of 6–15 ng/ml for 6 months. The primary endpoints were partial and complete remission rates at 6 months. Results Twelve (60%) patients achieved the primary end point with a 50% complete remission rate after 6 months. Among the 14 SLE patients, the overall response rate was 71.4%, with a complete remission rate of 64.3%. None of the primary Sjögren's syndrome cases responded to sirolimus. There was no significant difference in baseline clinical characteristics or lymphocyte subpopulations between responders and non-responders. No severe side effect was detected during the study. Conclusion Sirolimus is an effective and safe treatment option for refractory CTD-TP patients. Trial registration https://clinicaltrials.gov, NCT03688191.

Sign in / Sign up

Export Citation Format

Share Document